Wolf D - Search Results

1

High indoleamine-2,3-dioxygenase 1 (IDO) activity is linked to primary resistance to immunotherapy in non-small cell lung cancer (NSCLC).

Kocher F, Amann A, Zimmer K, Geisler S, Fuchs D, Pichler R, Wolf D, Kurz K, Seeber A, Pircher A. Kocher F, et al. Among authors: wolf d. Transl Lung Cancer Res. 2021 Jan;10(1):304-313. doi: 10.21037/tlcr-20-380. Transl Lung Cancer Res. 2021. PMID: 33569314 Free PMC article.

2

Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease.

Wolf AM, Wolf D, Rumpold H, Moschen AR, Kaser A, Obrist P, Fuchs D, Brandacher G, Winkler C, Geboes K, Rutgeerts P, Tilg H. Wolf AM, et al. Among authors: wolf d. Clin Immunol. 2004 Oct;113(1):47-55. doi: 10.1016/j.clim.2004.05.004. Clin Immunol. 2004. PMID: 15380529

3

Urinary neopterin does not reflect the local antitumor immune milieu in ovarian cancer.

Zeimet AG, Reimer D, Schwentner L, Fuchs D, Wolf D, Fuith LC, Fiegl H, Doppler W, Concin N, Daxenbichler G, Marth C. Zeimet AG, et al. Among authors: wolf d. Cancer Immunol Immunother. 2010 Dec;59(12):1813-23. doi: 10.1007/s00262-010-0907-0. Epub 2010 Aug 18. Cancer Immunol Immunother. 2010. PMID: 20717669 Free PMC article.

4

Durable complete remission in a patient with recurrent DLBCL receiving rituximab monotherapy after high-dose chemotherapy and autologous stem cell transplantation.

Pircher A, Gassner EM, Steurer M, Wolf D. Pircher A, et al. Among authors: wolf d. BMJ Case Rep. 2012 Jul 3;2012:bcr0220125856. doi: 10.1136/bcr.02.2012.5856. BMJ Case Rep. 2012. PMID: 22761205 Free PMC article.

5

Neoadjuvant chemo-immunotherapy modifies CD4(+)CD25(+) regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients.

Pircher A, Gamerith G, Amann A, Reinold S, Popper H, Gächter A, Pall G, Wöll E, Jamnig H, Gastl G, Wolf AM, Hilbe W, Wolf D. Pircher A, et al. Among authors: wolf d, wolf am. Lung Cancer. 2014 Jul;85(1):81-7. doi: 10.1016/j.lungcan.2014.04.001. Epub 2014 Apr 13. Lung Cancer. 2014. PMID: 24780112

6

Treg(s) in Cancer: Friends or Foe?

Wolf D, Sopper S, Pircher A, Gastl G, Wolf AM. Wolf D, et al. Among authors: wolf am. J Cell Physiol. 2015 Nov;230(11):2598-605. doi: 10.1002/jcp.25016. J Cell Physiol. 2015. PMID: 25913194 Review.

7

Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality.

Pircher A, Wolf D, Heidenreich A, Hilbe W, Pichler R, Heidegger I. Pircher A, et al. Among authors: wolf d. Int J Mol Sci. 2017 Oct 31;18(11):2291. doi: 10.3390/ijms18112291. Int J Mol Sci. 2017. PMID: 29088109 Free PMC article. Review.

8

Low-dose vemurafenib in hairy cell leukemia patients with active infection.

Bohn JP, Pircher A, Wanner D, Vill D, Foeger B, Wolf D, Steurer M. Bohn JP, et al. Among authors: wolf d. Am J Hematol. 2019 Jun;94(6):E180-E182. doi: 10.1002/ajh.25474. Epub 2019 Apr 4. Am J Hematol. 2019. PMID: 30916799 Free PMC article. No abstract available.

9

Curcumin: New Insights into an Ancient Ingredient against Cancer.

Willenbacher E, Khan SZ, Mujica SCA, Trapani D, Hussain S, Wolf D, Willenbacher W, Spizzo G, Seeber A. Willenbacher E, et al. Among authors: wolf d. Int J Mol Sci. 2019 Apr 12;20(8):1808. doi: 10.3390/ijms20081808. Int J Mol Sci. 2019. PMID: 31013694 Free PMC article. Review.

10

Angiogenesis inhibition in non-small cell lung cancer: a critical appraisal, basic concepts and updates from American Society for Clinical Oncology 2019.

Cantelmo AR, Dejos C, Kocher F, Hilbe W, Wolf D, Pircher A. Cantelmo AR, et al. Among authors: wolf d. Curr Opin Oncol. 2020 Jan;32(1):44-53. doi: 10.1097/CCO.0000000000000591. Curr Opin Oncol. 2020. PMID: 31609741 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,853 results

Search Page